Search by Drug Name or NDC
NDC 00074-7096-04 Qulipta 30 mg/1 Details
Qulipta 30 mg/1
Qulipta is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is ATOGEPANT.
MedlinePlus Drug Summary
Atogepant is used to help prevent migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light). Atogepant is in a class of medications called calcitonin gene-related peptide receptor antagonists. It works by blocking the action of a certain natural substance in the body that causes migraine headaches.
Related Packages: 00074-7096-04Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Atogepant
Product Information
| NDC | 00074-7096 |
|---|---|
| Product ID | 0074-7096_a313e1c3-0edb-4e39-b069-0c538f0c9424 |
| Associated GPIs | 67701010000320 |
| GCN Sequence Number | 082701 |
| GCN Sequence Number Description | atogepant TABLET 30 MG ORAL |
| HIC3 | H3F |
| HIC3 Description | ANTIMIGRAINE PREPARATIONS |
| GCN | 51232 |
| HICL Sequence Number | 047599 |
| HICL Sequence Number Description | ATOGEPANT |
| Brand/Generic | Brand |
| Proprietary Name | Qulipta |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Atogepant |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 30 |
| Active Ingredient Units | mg/1 |
| Substance Name | ATOGEPANT |
| Labeler Name | AbbVie Inc. |
| Pharmaceutical Class | Calcitonin Gene-related Peptide Receptor Antagonist [EPC], Calcitonin Gene-related Peptide Receptor Antagonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA215206 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00074-7096-04 (00074709604)
| NDC Package Code | 0074-7096-04 |
|---|---|
| Billing NDC | 00074709604 |
| Package | 4 TABLET in 1 BOTTLE (0074-7096-04) |
| Marketing Start Date | 2021-10-06 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |